Novo Nordisk 미래 성장

Future 기준 확인 4/6

Novo Nordisk (는) 각각 연간 14.4% 및 12.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 14.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 94.5% 로 예상됩니다.

주요 정보

14.4%

수익 성장률

14.7%

EPS 성장률

Pharmaceuticals 수익 성장	15.7%
매출 성장률	12.9%
향후 자기자본 수익률	94.5%
애널리스트 커버리지	Good
마지막 업데이트	15 Nov 2024

최근 미래 성장 업데이트

Novo Nordisk A/S (CPH:NOVO B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 09

Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

May 04

Recent updates

Solid Earnings May Not Tell The Whole Story For Novo Nordisk (CPH:NOVO B)

Nov 13

Novo Nordisk A/S (CPH:NOVO B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 09

Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

May 04

The Price Is Right For Novo Nordisk A/S (CPH:NOVO B)

Apr 28

Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?

Apr 14

Do Novo Nordisk's (CPH:NOVO B) Earnings Warrant Your Attention?

Mar 18

Novo Nordisk A/S' (CPH:NOVO B) Price In Tune With Earnings

Dec 30

Novo Nordisk (CPH:NOVO B) Seems To Use Debt Rather Sparingly

Dec 12

Estimating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Nov 24

수익 및 매출 성장 예측

CPSE:NOVO B - 애널리스트의 미래 추정치 및 과거 재무 데이터 (DKK Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	403,442	148,413	119,462	162,829	21
12/31/2025	343,304	124,807	94,089	139,559	24
12/31/2024	286,604	101,117	68,005	121,794	20
9/30/2024	270,583	94,721	67,031	118,218	N/A
6/30/2024	258,003	89,898	66,027	115,334	N/A
3/31/2024	244,243	89,276	50,304	93,408	N/A
12/31/2023	232,261	83,683	70,012	108,908	N/A
9/30/2023	214,490	75,312	77,825	106,458	N/A
6/30/2023	201,325	67,239	67,497	89,731	N/A
3/31/2023	188,290	61,129	67,341	85,115	N/A
12/31/2022	176,954	55,525	64,134	78,887	N/A
9/30/2022	167,195	52,825	57,875	68,769	N/A
6/30/2022	157,251	50,539	57,680	66,037	N/A
3/31/2022	149,027	49,344	59,665	67,331	N/A
12/31/2021	140,800	47,757	47,615	55,000	N/A
9/30/2021	134,605	46,183	40,213	58,189	N/A
6/30/2021	129,910	44,362	31,814	54,188	N/A
3/31/2021	126,875	42,864	31,337	53,194	N/A
12/31/2020	126,946	42,138	29,870	51,951	N/A
9/30/2020	127,225	41,537	44,800	56,944	N/A
6/30/2020	126,575	41,433	47,621	56,126	N/A
3/31/2020	126,605	40,403	36,987	46,904	N/A
12/31/2019	122,021	38,951	35,551	46,782	N/A
9/30/2019	119,336	38,731	36,785	49,029	N/A
6/30/2019	116,821	37,574	31,251	43,960	N/A
3/31/2019	114,192	38,322	32,202	44,691	N/A
12/31/2018	111,831	38,628	32,206	44,616	N/A
9/30/2018	110,091	38,384	31,576	43,236	N/A
6/30/2018	108,943	39,117	N/A	44,538	N/A
3/31/2018	110,174	38,725	N/A	38,885	N/A
12/31/2017	111,696	38,130	N/A	41,168	N/A
9/30/2017	113,276	38,576	N/A	46,289	N/A
6/30/2017	114,199	38,609	N/A	48,557	N/A
3/31/2017	113,020	38,626	N/A	52,937	N/A
12/31/2016	111,780	37,925	N/A	48,314	N/A
9/30/2016	111,084	37,484	N/A	47,280	N/A
6/30/2016	110,339	36,064	N/A	44,179	N/A
3/31/2016	109,939	34,439	N/A	41,656	N/A
12/31/2015	107,927	34,860	N/A	38,287	N/A
9/30/2015	103,636	33,131	N/A	35,469	N/A
6/30/2015	99,093	31,248	N/A	35,578	N/A
3/31/2015	93,663	29,899	N/A	31,729	N/A
12/31/2014	88,806	26,481	N/A	31,692	N/A
9/30/2014	85,919	26,005	N/A	29,763	N/A
6/30/2014	84,181	25,920	N/A	23,783	N/A
3/31/2014	83,932	25,660	N/A	22,941	N/A
12/31/2013	83,572	25,184	N/A	25,942	N/A

애널리스트 미래 성장 예측

수입 대 저축률: NOVO B 의 연간 예상 수익 증가율( 14.4% )이 saving rate( 1.2% 보다 높습니다. ).

수익 vs 시장: NOVO B 의 연간 수익( 14.4% ) Danish 시장( 11.6% 보다 빠르게 성장할 것으로 예상됩니다. 11.6% 연간).

고성장 수익: NOVO B 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: NOVO B 의 수익(연간 12.9% ) Danish 시장( 10% 보다 빠르게 성장할 것으로 예상됩니다. 10% 연간).

고성장 수익: NOVO B 의 수익(연간 12.9% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: NOVO B 의 자본 수익률은 3년 내에 매우 높을 것으로 예상됩니다( 94.5 %).

Novo Nordisk 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

Novo Nordisk A/S (CPH:NOVO B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Novo Nordisk A/S Provides Earnings Guidance for 2024

Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

Price target increased by 14% to kr.887

Novo Nordisk Revises Earnings Guidance for the Year 2023

Recent updates

Solid Earnings May Not Tell The Whole Story For Novo Nordisk (CPH:NOVO B)

Novo Nordisk A/S (CPH:NOVO B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Novo Nordisk A/S to Report Q2, 2025 Results on Aug 06, 2025

Third quarter 2024 earnings: EPS exceeds analyst expectations

Novo Nordisk A/S Provides Earnings Guidance for 2024

Novo Nordisk A/S Announces Results from Part 1 of the Ongoing ESSence Trial

Is Novo Nordisk A/S (CPH:NOVO B) Trading At A 31% Discount?

Novo Nordisk A/S' (CPH:NOVO B) P/E Still Appears To Be Reasonable

Novo Nordisk A/S Announces Monlunabant Phase 2A Trial in Obesity Successfully Completed

Aragen Life Sciences Reportedly Plans to Dilute About 10% Stake

Now 20% undervalued after recent price drop

Employee Representative Director recently sold kr.7.6m worth of stock

Now 20% undervalued after recent price drop

Second quarter 2024 earnings: EPS misses analyst expectations

Novo Nordisk A/S Decides to Pay Interim Dividend for 2024, Payable on 19 August 2024 for A and B Shares and 26 August 2024 for ADRs

Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

European Regulatory Authority Adopts A Positive Opinion for an Update of the Wegovy® Label to Reflect Risk Reduction of Major Adverse Cardiovascular Events

Novo Nordisk Receives Complete Response Letter in the US for Once-Weekly Basal Insulin Icodec

Should You Be Adding Novo Nordisk (CPH:NOVO B) To Your Watchlist Today?

A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations

Key Executive recently sold kr.50m worth of stock

Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

Novo Nordisk Announces Wegovy (Semaglutide Injection) Available in Canada

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

The Price Is Right For Novo Nordisk A/S (CPH:NOVO B)

Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Do Novo Nordisk's (CPH:NOVO B) Earnings Warrant Your Attention?

Final dividend of kr.6.40 announced

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

Price target increased by 14% to kr.887

President recently sold kr.145m worth of stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.

Novo Nordisk A/S Announces Topline Results from the Combine 3 Phase 3A Trial of Once-Weekly IcoSema

Novo Nordisk A/S' (CPH:NOVO B) Price In Tune With Earnings

Novo Nordisk (CPH:NOVO B) Seems To Use Debt Rather Sparingly

Estimating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Insider recently sold kr.10m worth of stock

Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk to Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, Flow, Based on Interim Analysis

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견